Employers Hold the Line on GLP-1 Coverage for Weight Loss
A new survey shows employer coverage of GLP-1 obesity drugs has barely budged, with many companies seeking workarounds rather than expanding benefits.
Employer adoption of GLP-1 drug coverage for obesity treatment has effectively stalled, according to new survey data, as companies grapple with the steep costs associated with blockbuster medications like Ozempic and Wegovy. Just 36% of employers now offer coverage of GLP-1s for both diabetes and weight loss — unchanged from 2025 figures and only marginally higher than the 34% recorded in 2024.
The near-flat trend suggests that despite surging patient demand and mounting clinical evidence supporting GLP-1s as effective obesity treatments, cost pressures are keeping the majority of employers on the sidelines. Rather than broadening coverage, many are quietly engineering workarounds — such as tightening eligibility criteria, requiring prior authorization, or capping the duration of benefits — to limit financial exposure without formally excluding the drugs.
Read more Blue Origin Valued at $130 Billion in First Outside Funding Round →
The stagnation is notable given the rapid rise of GLP-1 medications as a cultural and medical phenomenon. Analysts have long warned that widespread employer adoption could translate into billions of dollars in added pharmacy spend, making the cautious posture by HR and benefits teams understandable even as employee interest in the drugs continues to climb.
For workers hoping their workplace health plan will foot the bill for weight-loss prescriptions, the data underscores a widening gap between what medicine can offer and what benefits packages will actually cover. Employees at companies without GLP-1 obesity coverage may need to explore manufacturer discount programs, state-level insurance mandates, or out-of-pocket payment options to access the drugs.
Continue reading at US Top News and Analysis
